Cyclosporine Drugs Market Pegged for Robust Expansion by 2025

Posted by Aman Jaiswar on July 1st, 2019

Cyclosporines are calcineurin inhibitors belonging to the immunosuppressant agent class of drugs. It is a metabolite extracted from the Tolypocladium fungus. Cyclosporine is a potent immunosuppressive agent that prolongs existence of allogeneic transplants in the lungs, small intestines, pancreas, heart, skin, liver, kidneys, and bone marrow. Cyclosporine suppresses certain cell-mediated immune reactions such as allograft rejection, encephalomyelitis, Freund’s adjuvant arthritis, graft diseases, experimental allergy, and delayed hypersensitivity for a variety of organs and certain humoral immunity. Cyclosporine is sometimes prescribed for patients with autoimmune myasthenia gravis in order to treat dry eye.

According to the National Institute of Environmental Health Sciences, more than 80 autoimmune diseases have been identified. Some of them are diabetes (type 1), lupus, multiple sclerosis, rheumatoid arthritis, and celiac disease. Rise in the prevalence of these diseases drives the global Cyclosporine Drugs Market. Increasing low birth weight associated with the development of rheumatoid arthritis as an adult drive the cyclosporine drugs market. The exposure to solvents such as nail polish, cleaning supplies, paint thinners, and others increase the prevalence of allergic diseases thus increasing the demand of cyclosporine drugs.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32183

Increasing inclination toward smoking leads to development of two types of rheumatoid arthritis. This, in turn, increases the demand for cyclosporine drugs. Exposure to granite, fine particles of crystalline silica, and other minerals increases the risk of developing autoimmune diseases. Laborers exposed to these minerals are particularly at a high risk. This factor augments the demand for cyclosporine drugs. However, certain adverse drug reactions caused by cyclosporine including renal dysfunction, tremors, hirsutism, hypertension, and gum hyperplasia restrain the market for cyclosporine drugs.

The global cyclosporine drugs market can be segmented based on drug form, patient type, indication type, end-user, and region. In terms of drug form, the market can be categorized into capsules, oral solutions, and injections. Based on patient type, the market can be classified into pediatric patients, adult patients, and geriatric patients. In terms of indication type, the market can be divided into transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, autoimmune myasthenia gravis, dry eye, and others. Based on end-user, the market can be segmented into hospital pharmacies, specialized clinics, retail pharmacies, and online pharmacies.

Key players operating in the global cyclosporine drugs market are Allergan, Novartis AG, Apotex Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.